Active, not recruitingPhase 4NCT06013969
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
Studying DITRA
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boehringer Ingelheim
- Intervention
- Spesolimab(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- University of California Irvine, Irvine, California, United States
- Red River Research Partners, LLC, Fargo, North Dakota, United States
- Liverpool Hospital, Liverpool, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Hospital Universitario Evangelico Mackenzie, Curitiba, Brazil
- Faculdade de Medicina do ABC, Santo André, Brazil
- Southern Medical University Dermatology Hospital, Guangzhou, China
- Shanghai Skin Disease Hospital, Shanghai, China
- Shanghai Tenth People's Hospital, Shanghai, China
- HOP Trousseau, Chambray-lès-Tours, France
- HOP Saint-Louis, Paris, France
- Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
- Klinikum der Universität München AÖR, München, Germany
- SP medical college and associated group of hospitals, Bikaner, India
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06013969 on ClinicalTrials.govOther trials for DITRA
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552454Picankibart in Palmoplantar PustulosisXijing Hospital
- RECRUITINGPHASE2NCT07314060A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGNCT06952465A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisBristol-Myers Squibb
- RECRUITINGPHASE2, PHASE3NCT06477536Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular PsoriasisShanghai Huaota Biopharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT06433531A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06323356A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisTakeda
- ACTIVE NOT RECRUITINGPHASE3NCT06295692A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisJanssen Pharmaceutical K.K.
- RECRUITINGNCT06100991CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness RegistryCorEvitas